Young Tae Kim and Min Zhao 63:226-30. 15. Sano T, Masuda N, Oyama T, Nakajima T. Overex- pression of p16 and p14ARF is associated with human papillomavirus infection in cervical squamous cell carcinoma and dysplasia. Pathol Int 2002;52:375-83. 16. Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001;92:276-84. 17. Marjoniemi VM. Immunohistochemistry in gynaecolo- gical pathology: a review. Pathology 2004;36:109-19. 18. Volgareva G, Zavalishina L, Andreeva Y, Frank G, Krutikova E, Golovina D, et al. Protein p16 as a marker of dysplastic and neoplastic alterations in cervical epithelial cells. BMC Cancer 2004;4:58. 19. Giarre M, Caldeira S, Malanchi I, Ciccolini F, Leao MJ, Tommasino M. Induction of pRb degradation by the human papillomavirus type 16 E7 protein is essential to efficiently overcome p16INK4a-imposed G1 cell cycle Arrest. J Virol 2001;75:4705-12. 20. Von Knebel Doeberitz M. New molecular tools for efficient screening of cervical cancer. Dis Markers 2001; 17:123-8. 21. Murphy N, Ring M, Killalea AG, Uhlmann V, O'Donovan M, Mulcahy F, et al. p16INK4A as a marker for cervical dyskaryosis: CIN and cGIN in cervical biopsies and ThinPrep smears. J Clin Pathol 2003;56: 56-63. 22. Guo M, Hu L, Baliga M, He Z, Hughson MD. The predictive value of p16(INK4a) and hybrid capture 2 human papillomavirus testing for high-grade cervical intraepithelial neoplasia. Am J Clin Pathol 2004;122: 894-901. 23. Saqi A, Pasha TL, McGrath CM, Yu GH, Zhang P, Gupta P. Overexpression of p16INK4A in liquid-based specimens (SurePath) as marker of cervical dysplasia and neoplasia. Diagn Cytopathol 2002;27:365-70. 24. Hu L, Guo M, He Z, Thornton J, McDaniel LS, Hughson MD. Human papillomavirus genotyping and p16INK4a expression in cervical intraepithelial neo- plasia of adolescents. Mod Pathol 2005;18:267-73. 25. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Mini- review: Cyclin D1: normal and abnormal functions. Endocrinology 2004;145:5439-47. 26. Reutens AT, Fu M, Wang C, Albanese C, McPhaul MJ, Sun Z, et al. Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/ CBP-associated factor (P/CAF)-dependent manner. Mol Endocrinol 2001;15:797-811. 27. Wang C, Pattabiraman N, Zhou JN, Fu M, Sakamaki T, Albanese C, et al. Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation. Mol Cell Biol 2003;23:6159-73. 28. Cho NH, Kim YT, Kim JW. Correlation between G1 cyclins and HPV in the uterine cervix. Int J Gynecol Pathol 1997;16:339-47. 29. Bae DS, Cho SB, Kim YJ, Whang JD, Song SY, Park CS, et al. Aberrant expression of cyclin D1 is associated Yonsei Med J Vol. 46, No. 5, 2005 with poor prognosis in early stage cervical cancer of the uterus. Gynecol Oncol 2001;81:341-7. 30. Southern SA, Herrington CS. Differential cell cycle regulation by low- and high-risk human papilloma- viruses in low-grade squamous intraepithelial lesions of the cervix. Cancer Res 1998;58:2941-5. 31. Nichols GE, Williams ME, Gaffey MJ, Stoler MH. Cyclin D1 gene expression in human cervical neoplasia. Mod Pathol 1996;9:418-25. 32. Kurzrock R, Ku S, Talpaz M. Abnormalities in the PRAD1 (CYCLIN D1/BCL-1) oncogene are frequent in cervical and vulvar squamous cell carcinoma cell lines. Cancer. 1995;75:584-90. 33. Skomedal H, Kristensen GB, Lie AK, Holm R. Aberrant expression of the cell cycle associated proteins TP53, MDM2, p21, p27, CDK4, cyclin D1, RB, and EGFR in cervical carcinomas. Gynecol Oncol 1999;73:223-8. 34. Cheung TH, Yu MM, Lo KW, Yim SF, Chung TK, Wong YF. Alteration of cyclin D1 and CDK4 gene in carcinoma of uterine cervix. Cancer Lett 2001;166:199- 206. 35. Psyrri A, DeFilippis RA, Edwards AP, Yates KE, Manuelidis L, DiMaio D. Role of the retinoblastoma pathway in senescence triggered by repression of the human papillomavirus E7 protein in cervical carcinoma cells. Cancer Res 2004;64:3079-86. 36. Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes Dev 2004;18:2699- 711. 37. Grana X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 1995;11:211-9. 38. Yoshinouchi M, Hongo A, Takamoto N, Ono Y, Nagao S, Miyagi Y, et al. Alteration of the CDKN2/p16 gene is not required for HPV positive uterine cervical cancer cell lines. Int J Oncol 2000;16:534-41. 39. Matsuura I, Denissova NG, Wang G, He D, Long J, Liu F. Cyclin-dependent kinases regulate the antiprolifera- tive function of Smads. Nature 2004;8,430:226-31. 40. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell 1994;78:67-74. 41. Hall M, Bates S, Peters G. Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene 1995;11:1581-8. 42. Lukas J, Muller H, Bartkova J, Spitkovsky D, Kjerulff AA, Jansen-Durr P, et al. DNA tumor virus onco- proteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1. J Cell Biol 1994;125:625-38. 43. Salcedo M, Taja L, Utrera D, Chavez P, Hidalgo A, Perez C, et al. Changes in retinoblastoma gene expres- sion during cervical cancer progression. Int J Exp Pathol 2002;83:275-86. 44. Muller H, Lukas J, Schneider A, Warthoe P, Bartek J, Eilers M, et al. Cyclin D1 expression is regulated by the